Cargando…

MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective in patients with non–small‐cell lung cancer (NSCLC) harboring EGFR mutations. However, due to acquired resistance to EGFR‐TKIs, even patients on third‐generation osimertinib have a poor prognosis. Resistance mechan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yiming, Reheman, Takeuchi, Yasuto, Nishimura, Tatsunori, Li, Mengjiao, Wang, Yuming, Meguro‐Horike, Makiko, Kohno, Takashi, Horike, Shin‐ichi, Nakata, Asuka, Gotoh, Noriko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409425/ https://www.ncbi.nlm.nih.gov/pubmed/34145929 http://dx.doi.org/10.1111/cas.15036

Ejemplares similares

Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2
por: Nishimura, Tatsunori, et al.
Publicado: (2018)

Topical estrogen application promotes cutaneous wound healing in db/db female mice with type 2 diabetes
por: Mukai, Kanae, et al.
Publicado: (2022)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

First report of inherited protein S deficiency caused by paternal PROS1 mosaicism
por: Nagaya, Satomi, et al.
Publicado: (2021)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

UBE3A-mediated regulation of imprinted genes and epigenome-wide marks in human neurons
por: Lopez, S. Jesse, et al.
Publicado: (2017)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Epigenetic Regulation of Aldosterone Synthase Gene by Sodium and Angiotensin II
por: Takeda, Yoshimichi, et al.
Publicado: (2018)

Functional Investigation of a Non-coding Variant Associated with Adolescent Idiopathic Scoliosis in Zebrafish: Elevated Expression of the Ladybird Homeobox Gene Causes Body Axis Deformation
por: Guo, Long, et al.
Publicado: (2016)

Potential therapeutic target secretogranin II might cooperate with hypoxia‐inducible factor 1α in sunitinib‐resistant renal cell carcinoma
por: Fukumoto, Wataru, et al.
Publicado: (2023)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
por: Igawa, Satoshi, et al.
Publicado: (2019)

Inflammatory cytokine‐enriched microenvironment plays key roles in the development of breast cancers
por: Takeuchi, Yasuto, et al.
Publicado: (2023)

Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice
por: Taketani, Hiroyoshi, et al.
Publicado: (2019)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
por: Osoegawa, Atsushi, et al.
Publicado: (2021)

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer
por: Lu, Yingjie, et al.
Publicado: (2021)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
por: Xiang, Chan, et al.
Publicado: (2021)

The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare EGFR R776H mutation with Osimertinib: Case report
por: Cui, Joyce, et al.
Publicado: (2023)

De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report
por: Ding, Yingying, et al.
Publicado: (2022)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Impact of Musashi-1 and Musashi-2 Double Knockdown on Notch Signaling and the Pathogenesis of Endometriosis
por: Strauß, Theresa, et al.
Publicado: (2022)

Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer
por: Andrade, Fernando, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
por: Yamauchi, Mai, et al.
Publicado: (2012)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
por: Li, Chenguang, et al.
Publicado: (2018)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2019)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

FRI291 Musashi1 And Musashi2 Mark Distinct Pituitary Stem Cell Populations
por: Rahmatallah, Yasir, et al.
Publicado: (2023)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin
por: Bian, Shuang, et al.
Publicado: (2020)

Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2021)

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h8dumid2h44g9jgk3v4090f8m0